You are here

Theratechnologies Provides Update on Trogarzo™ (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status

MONTREAL, May 16, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX:TH) today disclosed, during its annual meeting, information on the number of scripts and reimbursement coverage for Trogarzo™ in the United States.

“We are quite pleased with the reaction from patients, physicians and payers since we announced the commercial availability of Trogarzo™ on April 30, 2018,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc. “It did not take long to observe strong interest from HIV clinics and to obtain reimbursement from public and private payers,” added Mr. Tanguay.

“Major private insurers such as Cigna, Aetna, United Healthcare and Kaiser Permanente have already amended their reimbursement policy to include Trogarzo™. As we stand, about 25% of privately insured lives in the U.S. now have access to Trogarzo™. In addition, Medicare has quickly made it possible to approve individual requests. Medicaid coverage has been secured in California and Florida, among others, which, together, represent close to 20% of patients covered under Medicaid state plans. All this happened just two months after approval,” said Mr. Tanguay.

“While symbolic, we will reach the 100 prescription milestone within three weeks of commercial availability, which is reason to be optimistic about the demand for Trogarzo™,” added Mr. Tanguay.

“Our entire team continues to work very hard to quickly bring this unique product to patients faced with the challenge of multidrug resistant HIV,” concluded Mr. Tanguay.

About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.

Forward-Looking Information
This press release contains statements that are considered forward-looking information (“FLI”) within the meaning of securities laws that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, the number of prescriptions for TrogarzoTM and the availability of TrogarzoTM to as many patients with multidrug resistant HIV-1 as possible.

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include but are not limited to, the following: the number of prescriptions for TrogarzoTM will continue to increase over time and the level of reimbursement by public and private payers will also continue to grow. These risks and uncertainties include, but are not limited to, the risk that the number of patients suffering from multidrug resistant HIV-1 is less than anticipated, thereby decreasing the number of prescriptions for TrogarzoTM, the risk that physicians do not value TrogarzoTM as a treatment for HIV-patients faced with multidrug resistance, the risk that private and/or public payers do not reimburse TrogarzoTM or impose restrictions as a condition to reimbursing TrogarzoTM, all of which could lead to a restriction on the availability of TrogarzoTM for patients.

We refer potential investors to the “Risk Factors” section of our Annual Information Form (AIF) dated February 6, 2018 for additional risks and uncertainties about Theratechnologies. The AIF is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Information:
Denis Boucher
Vice President, Communications and Corporate Affairs
514-336-7800 ext. 236

Wednesday, May 16, 2018 - 11:30